SSM Predicts Outcomes of CLD Inpatients With Acute Liver Injury

Last updated: May 19, 2025
Sponsor: Nanfang Hospital, Southern Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Circulation Disorders

Williams Syndrome

Diabetes And Hypertension

Treatment

FibroScan® Expert 630

Clinical Study ID

NCT06173947
NFEC-2023-495
  • Ages 18-80
  • All Genders

Study Summary

In this study, a single non-invasive tool, spleen stiffness measurement (SSM), was used to monitor the disease regression of inpatients with chronic liver disease (CLD) and acute liver injury. The present study aimed to establish an early diagnosis warning model for acute-on-chronic liver failure (ACLF) by SSM and investigate the effect of dynamic changes in SSM on the short-term prognosis (28-day, 90-day morbidity and mortality) of inpatients with CLD and acute liver injury.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age between 18 years and 80 years

  2. Chronic liver diseases regardless of etiology

  3. Acute liver injury with total bilirubin ≥ 3 mg/dl regardless of inducement

Exclusion

Exclusion Criteria:

  1. Prior surgery of liver diseases before enrollment such as liver transplantation,transjugular intrahepatic portosystemic shunt (TIPS), splenectomy and partialsplenic embolization

  2. Severe extrahepatic diseases such as chronic obstructive pulmonary disease level IV,chronic kidney disease with end-stage renal failure, myocardial infarction within 3months before admission

  3. Receiving Immunosuppressive drugs for reasons rather than chronic liver diseases

  4. Diagnosis of hepatocellular carcinoma or other non-liver malignancies duringscreening period

  5. Serious mental illnesses such as anxiety, depressive disorders toobsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD)

  6. The pregnant

  7. Jaundice due to biliary obstruction or cholestasis

  8. Unsuitable to participate in this study judging by investigators

Study Design

Total Participants: 411
Treatment Group(s): 1
Primary Treatment: FibroScan® Expert 630
Phase:
Study Start date:
January 01, 2024
Estimated Completion Date:
December 30, 2025

Study Description

Portal hypertension is a major complication of cirrhosis and can lead to serious clinical manifestations such as ascites, hepatic encephalopathy, variceal bleeding, etc. Colecchia et al. proposed the use of spleen stiffness measurement (SSM) to dynamically monitor portal pressure and to predict the risk of oesophageal varices. Studies have now demonstrated the utility of SSM in assessing portal hypertension, ruling out high-risk varices, and predicting clinical complications in cirrhotic patients. Furthermore, the Baveno VII consensus of portal hypertension has included SSM in its recommendations for non-invasive screening. Pathogenic triggers, important clinical events (ascites, encephalopathy, etc.), and short-term prognosis in compensated advanced chronic liver disease are associated with portal pressure. Exploring the relationship between portal hypertension and liver failure development would be of great clinical and scientific value. The present study is mainly based on a single non-invasive tool, SSM, to monitor the disease regression of chronic liver disease (CLD) inpatients with acute liver injury, to establish an early warning model for early diagnosis of acute-on-chronic liver failure, and to investigate the effect of dynamic changes in SSM on the short-term prognosis of inpatients with CLD and acute liver injury.

Connect with a study center

  • Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong 510515
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.